Healthcare provider profile · identity verified

Pablo Rivera Vale, M.D.

General Practice · MOCA, PR · NPI 1073561569

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Gabapentin	Gabapentin	305	46
Losartan Potassium	Losartan Potassium	234	43
Famotidine	Famotidine	221	71
Atorvastatin Calcium	Atorvastatin Calcium	217	37
Rosuvastatin Calcium	Rosuvastatin Calcium	214	48
Simvastatin	Simvastatin	184	26
Synthroid	Levothyroxine Sodium	184	32
Omeprazole	Omeprazole	172	31
Clonazepam	Clonazepam	171	31
Metformin Hcl	Metformin Hcl	158	28
Glimepiride	Glimepiride	151	26
Sertraline Hcl	Sertraline Hcl	148	25
Amlodipine Besylate	Amlodipine Besylate	135	26
Tamsulosin Hcl	Tamsulosin Hcl	103	21
Azithromycin	Azithromycin	92	81
Etodolac	Etodolac	90	68
Irbesartan	Irbesartan	90	14
Metoprolol Succinate	Metoprolol Succinate	90	16
Lisinopril	Lisinopril	86	17
Pantoprazole Sodium	Pantoprazole Sodium	84	19
Levothyroxine Sodium	Levothyroxine Sodium	80	13
Albuterol Sulfate Hfa	Albuterol Sulfate	77	17
Alprazolam	Alprazolam	74	12
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	72	suppressed
Carvedilol	Carvedilol	68	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	68	12
Meloxicam	Meloxicam	68	28
Atenolol	Atenolol	64	suppressed
Enalapril Maleate	Enalapril Maleate	59	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	58	suppressed
Dexamethasone	Dexamethasone	57	45
Clopidogrel	Clopidogrel Bisulfate	54	suppressed
Montelukast Sodium	Montelukast Sodium	53	13
Trazodone Hcl	Trazodone Hcl	53	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	48	45
Fluoxetine Hcl	Fluoxetine Hcl	48	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	47	suppressed
Nabumetone	Nabumetone	47	16
Tramadol Hcl	Tramadol Hcl	47	27
Diclofenac Sodium	Diclofenac Sodium	46	20
Furosemide	Furosemide	45	11
Lansoprazole	Lansoprazole	43	suppressed
Lorazepam	Lorazepam	42	suppressed
Temazepam	Temazepam	42	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	40	suppressed
Levofloxacin	Levofloxacin	38	35
Quetiapine Fumarate	Quetiapine Fumarate	38	suppressed
Paroxetine Hcl	Paroxetine Hcl	35	suppressed
Donepezil Hcl	Donepezil Hcl	32	suppressed
Ibandronate Sodium	Ibandronate Sodium	32	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	32	suppressed
Ezetimibe	Ezetimibe	31	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	30	suppressed
Eliquis	Apixaban	30	suppressed
Memantine Hcl	Memantine Hcl	30	suppressed
Buspirone Hcl	Buspirone Hcl	29	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	28	suppressed
Orphenadrine Citrate Er	Orphenadrine Citrate	28	24
Baclofen	Baclofen	27	suppressed
Finasteride	Finasteride	27	suppressed
Pentoxifylline	Pentoxifylline	27	suppressed
Sulindac	Sulindac	27	19
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	27	suppressed
Fenofibrate	Fenofibrate	26	suppressed
Meclizine Hcl	Meclizine Hcl	26	21
Spironolactone	Spironolactone	26	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	25	suppressed
Naproxen	Naproxen	25	suppressed
Risperidone	Risperidone	25	suppressed
Alendronate Sodium	Alendronate Sodium	24	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	24	19
Ketorolac Tromethamine	Ketorolac Tromethamine	24	24
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	23	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	23	suppressed
Divalproex Sodium	Divalproex Sodium	23	suppressed
Ondansetron Hcl	Ondansetron Hcl	22	21
Tizanidine Hcl	Tizanidine Hcl	21	14
Escitalopram Oxalate	Escitalopram Oxalate	20	suppressed
Levetiracetam	Levetiracetam	20	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	20	suppressed
Bupropion Xl	Bupropion Hcl	19	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	19	14
Farxiga	Dapagliflozin Propanediol	19	suppressed
Fluticasone Propionate	Fluticasone Propionate	19	suppressed
Betamethasone Dipropionate	Betamethasone Dipropionate	18	suppressed
Diclofenac Potassium	Diclofenac Potassium	17	14
Sucralfate	Sucralfate	17	suppressed
Sure Comfort	Syringe And Needle,insulin,1ml	17	suppressed
Glipizide	Glipizide	16	suppressed
Insulin Syringe	Syringe And Needle,insulin,1ml	16	suppressed
Galantamine Hbr	Galantamine Hbr	15	suppressed
Ibuprofen	Ibuprofen	15	suppressed
Prednisone	Prednisone	15	suppressed
Tramadol Hcl-Acetaminophen	Tramadol Hcl/Acetaminophen	15	14
Clindamycin Hcl	Clindamycin Hcl	14	14
Doxepin Hcl	Doxepin Hcl	14	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	14	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Cilostazol	Cilostazol	13	suppressed
Citalopram Hbr	Citalopram Hydrobromide	13	suppressed
Naproxen Sodium	Naproxen Sodium	13	suppressed
Sure Comfort	Syringe-Needle,insulin,0.5 Ml	13	suppressed
Digoxin	Digoxin	12	suppressed
Dilantin	Phenytoin Sodium Extended	12	suppressed
Fenofibric Acid	Fenofibric Acid (Choline)	12	suppressed
Glyburide-Metformin Hcl	Glyburide/Metformin Hcl	12	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	12	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	12	suppressed
Topiramate	Topiramate	12	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	11	suppressed
Humalog	Insulin Lispro	11	suppressed
Naltrexone Hcl	Naltrexone Hcl	11	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	11	suppressed
Silodosin	Silodosin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error